Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how pharmacokinetic equivalency across varied patient weights supports flat dosing, ...

Establishing equivalency between subcutaneous and IV formulations requires rigorous evaluation across multiple domains. Regulatory approval studies focus on demonstrating comparable pharmacokinetics, ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced that an update on the clinical development plan and pre-clinical data with SubQ-8 were presented today in a scientific symposium at the 27th ...

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the ...

A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence ...

A subcutaneous dose of the second-generation glycoprotein IIb/IIIa inhibitor RUC-4 achieved rapid dose-dependent platelet inhibition in patients with ST-segment myocardial infarction (STEMI) ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.

Medroxyprogesterone acetate 104mg/0.65mL; SC inj; contains parabens. Medroxyprogesterone acetate inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation ...